Beijing Luzhu Biotechnology Co., Ltd. (LUZHU BIOTECH) has filed its Monthly Return for Equity Issuer for the period ended 31 May 2026, indicating no changes in either its registered capital or share structure during the month.

The company’s issued share capital stood unchanged at 202.45 million ordinary H shares, each with a par value of RMB 1, translating into registered share capital of RMB 202.45 million. Of these, 198.91 million shares remain in circulation, while 3.54 million are held as treasury shares—figures identical to the preceding month.

Luzhu Biotech confirmed compliance with the Hong Kong Stock Exchange’s minimum public-float requirement of 25% of issued shares (excluding treasury shares). Based on publicly available information, management stated that the threshold was met as at 31 May 2026.

No new share options, warrants, convertible securities, or other equity-linked instruments were issued, exercised, or cancelled during the month, and there were no other movements involving treasury shares.

The confirmation was signed by Joint Company Secretary Liu Siyu on 2 June 2026, affirming that all statutory and listing-rule obligations were satisfied in relation to the company’s securities for the reporting period.